The Berkeley biotech is backing a Nature-published approach that recreates the embryonic environment where blood stem cells first form, rather than reprogramming aged cells chemically or genetically. Its lead programme targets bone marrow transplant in blood cancers and has received FDA Orphan Drug Designation. HexemBio has publicly launched with a $10.4 million seed round led […]<br /> This story continues at The Next Web [...]
Language models on the therapy couch: researchers at the University of Luxembourg treat ChatGPT, Gemini and Grok like patients - with disturbing consequences. The AI invents consistent trauma biograph [...]
Ubisoft still isn’t giving us a new Splinter Cell game, but Sam Fisher fans are at least getting an animated TV adaptation very soon. At this week’s Anime NYC convention, Netflix revealed a new te [...]
The European Investment Bank is lending €20 million to BioLamina, the Swedish biotech that supplies the laminin-based cell culture matrices used by stem cell therapy developers worldwide. The fundin [...]
A team of doctors and scientists have successfully treated a rare genetic condition with the first-ever personalized gene-editing therapy. Results of the groundbreaking treatment have been published i [...]
It’s harvest day at the Karolinska Institute in Stockholm. As sunshine bathes the leafy university campus, scientists inside the labs work under cool fluorescent light. Clad in green protective gear [...]